Despite encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. The organizations are often erecting limitations to reimbursement, like significant cost criteria and prior authorization that limit user opportunity. In